<DOC>
	<DOCNO>NCT00282724</DOCNO>
	<brief_summary>Lamellar ichthyosis congenital disease skin generalize scaling . The primary activity liarozole consider inhibition degradation substance call retinoic acid , principal endogenous regulator growth differentiation epithelial tissue mammal . The current study intend evaluate efficacy safety patient lamellar ichthyosis .</brief_summary>
	<brief_title>Efficacy Safety Two Doses Liarozole v . Placebo Treatment Lamellar Ichthyosis</brief_title>
	<detailed_description>Lamellar ichthyosis autosomal recessive disorder apparent birth present throughout life . Although disorder life threatening , quite disfigure cause considerable psychological stress affect patient . Prevalence le 1 case per 300,000 individual . Treatment mainly symptomatic i.e . emollient without keratolytic agent . Treatment systemic retinoids reserve patient , refractory conventional therapy , long-term adverse effect teratogenicity systemic retinoids . Liarozole may provide new concept treatment condition . Because mechanism action , retinoic acid ( RA ) level increase tissue target RA production . The proposed Phase II/III study intend evaluate efficacy liarozole compare placebo , patient lamellar ichthyosis .</detailed_description>
	<mesh_term>Ichthyosis</mesh_term>
	<mesh_term>Ichthyosis , Lamellar</mesh_term>
	<mesh_term>Liarozole</mesh_term>
	<criteria>Subjects either sex age 14 year old . Clinical diagnosis lamellar ichthyosis Women childbearing potential use appropriate contraception Women childbearing potential negative pregnancy test screen visit . Subjects , except lamellar ichthyosis , good general health . Subjects legal representative ( ) , applicable , sign informed consent . Subject receive topical ( except emollient ) , UV treatment systemic treatment ichthyosis . Subject pregnant breast feeding . History suspicion alcohol drug abuse . Significant coexisting disease . Clinically significant abnormal ECG History hypersensitivity retinoids ingredient trial medication . Clinically relevant laboratory abnormality screen . Use immunesuppressive drug include topical systemic corticosteroid . Participation investigational trial 30 day prior start trial .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Lamellar ichthyosis</keyword>
	<keyword>Liarozole</keyword>
	<keyword>Investigator 's Global Assessment</keyword>
	<keyword>Scaling</keyword>
</DOC>